Oruka’s Long-Acting Psoriasis Drug Hits 63.5% Complete Skin Clearance in Mid-Stage Trial
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Piper Sandler gives Oruka Therapeutics an Overweight rating, highlighting its unique antibody portfolio, ORKA-001 validation, and a promising 2026 catalyst-rich year.
Guggenheim starts coverage of Oruka Therapeutics with Buy rating and $60 target, praising its longer-acting antibody drugs for chronic inflammation treatment.
Oruka Therapeutics shares jump 30% as analysts predict gains following competitor MoonLake's Phase 3 results.
ORKA-001, Oruka's new psoriasis drug, shows a 100-day half-life, making once-a-year dosing possible. It aims for higher skin clearance and long-term remission with a good safety profile. Phase 2 data is expected in late 2026. This could redefine treatment!